ArticleJournal for immunotherapy of cancer2021
Therapeutic depletion of CCR8
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 1 synthesis or guideline pooled it, 195 citations in OpenAlex.
- Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.Frontiers in immunology · 2021Pooled it
- Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.Cell reports. Medicine · 2026Trial
- Article
- IL7R mRNA therapy enhances antitumor T cell immunity and suppresses tumor growth in preclinical tumor models.Journal for immunotherapy of cancer · 2026Article
- Resistance to PD-1/PD-L1 blockade: Mechanism and pharmacological strategies.Pharmacological research · 2026Review
- Targeting KRAS reprograms a Treg-dominant immunosuppressive microenvironment and sensitizes KRAS-mutant gastric adenocarcinoma to CTLA-4 immunotherapy.Science China. Life sciences · 2026Article
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- Regulatory T Cells in Hepatocellular Carcinoma: Spatial Niches, Biomarkers, and Clinical Implications.International journal of molecular sciences · 2026Review
- The Immune Landscape of Acral Melanoma: From Basic to Clinical.Cancer medicine · 2026Review
- The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog-mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis.Clinical and translational medicine · 2026Article
- CCR8 orchestrates an immunosuppressive niche in the liver to promote Echinococcus multilocularis infection.PLoS neglected tropical diseases · 2026Article
- A DNA nanoflowers-based microneedle patch for transdermal gene and photodynamic therapy against melanoma.Journal of nanobiotechnology · 2026Article
- Decoding signaling architectures: CAR versus TCR dynamics in solid tumor immunotherapy.Acta biochimica et biophysica Sinica · 2026Review
- Regulatory T Cells Along the Pancreatitis-Pancreatic Cancer Continuum: Context-Dependent Immune Control and Therapeutic Opportunities.International journal of general medicine · 2026Review
- Immunosuppressive cells as barriers to cancer therapy: mechanisms and emerging solutions.Frontiers in immunology · 2026Review
- Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation.Small science · 2026Review
- Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer.Frontiers in cell and developmental biology · 2026Review
- Beyond Foxp3 and TSDR: a dual epigenetic lock framework for treg stability and plasticity.Frontiers in immunology · 2026Review
- Effect of programmed cell death protein-1 inhibitor combined with platinum-containing dual-agent chemotherapy regimen on gut microbiota in Lewis lung cancer model mice.Frontiers in microbiology · 2026Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 11 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundModulation and depletion strategies of regulatory T cells (Tregs) constitute valid approaches in antitumor immunotherapy but suffer from severe adverse effects due to their lack of selectivity for the tumor-infiltrating (ti-)Treg population, indicating the need for a ti-Treg specific biomarker.
methodsWe employed single-cell RNA-sequencing in a mouse model of non-small cell lung carcinoma (NSCLC) to obtain a comprehensive overview of the tumor-infiltrating T-cell compartment, with a focus on ti-Treg subpopulations. These findings were validated by flow cytometric analysis of both mouse (LLC-OVA, MC38 and B16-OVA) and human (NSCLC and melanoma) tumor samples. We generated two CCR8-specific nanobodies (Nbs) that recognize distinct epitopes on the CCR8 extracellular domain. These Nbs were formulated as tetravalent Nb-Fc fusion proteins for optimal CCR8 binding and blocking, containing either an antibody-dependent cell-mediated cytotoxicity (ADCC)-deficient or an ADCC-prone Fc region. The therapeutic use of these Nb-Fc fusion proteins was evaluated, either as monotherapy or as combination therapy with anti-programmed cell death protein-1 (anti-PD-1), in both the LLC-OVA and MC38 mouse models.
resultsWe were able to discern two ti-Treg populations, one of which is characterized by the unique expression of
conclusionsCollectively, our findings highlight the efficacy and safety of targeting CCR8 for the depletion of tumor-promoting ti-Tregs in combination with anti-PD-1 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.